respectively, was evaluated in implanted and genetically engineered mouse models of lymphoma and in a human colorectal xenograft. Results: The fluorophore labeled C2Am derivative showed predominantly renal clearance and high specificity and sensitivity for detecting low levels of tumor cell death (2-5%). There was a significant correlation (R>0.9, P<0.05) between fluorescently-labeled C2Am binding and histological markers of cell death, including cleaved caspase-3, whereas there was no such correlation with a site-directed mutant of C2Am (iC2Am) that does not bind phosphatidylserine. In-C2Am also showed favorable biodistribution profiles, with predominantly renal clearance and low non-specific retention in liver and spleen at 24 h after probe administration. In-C2Am generated tumor-to-muscle ratios in drug-treated tumors of 4.3× and 2.2× respectively at two hours and 7.3× and 4.1× respectively at twenty-four hours after administration. Conclusions: Given the favorable biodistribution profile of 99m In-labelled C2Am, and their ability to produce rapid and cell death-specific image contrast, these agents have potential for clinical translation.
Detection of the early responses of tumors to therapy would allow rapid selection of the most effective treatment. Currently, clinical assessment of treatment response is based on Response Evaluation Criteria in Solid Tumors (RECIST), which define partial response as a reduction of at least 30% in the sum of the diameters of the target lesion (1) . The problem for early detection of response is that these morphological changes may only occur weeks after the start of treatment and fail to detect response to cytostatic therapies (2) .
Cell death is an important target for imaging early treatment response (3), since most treatments induce tumor apoptosis and/or necrosis. However, there is as yet no reliable technique for routine imaging of cell death in the clinic (4) . Phosphatidylserine, which is externalized on the outer leaflet of the plasma membrane bilayer in apoptosis, and is exposed through permeabilization of the plasma membrane in necrotic cells, can be detected using the 36-kDa phosphatidylserine-binding protein, Annexin-V (AnxV) (5) . Tc-labeled AnxV has been used to image drug-induced cell death in human tumors, including breast, lymphoma, lung (6) and head and neck squamous cell carcinoma (7).
However, despite early promise, and the development of novel site-directed mutants of AnxV with improved biodistribution (8) , problems with this agent persisted (9) , including suboptimal pharmacokinetics and non-specific binding (10) .
We have developed a phosphatidylserine-targeted agent based on the C2A domain of Synaptotagmin-I. This was first used, in animal models, in the form of a dimeric glutathione S-transferase (GST)-tagged construct (84 kDa) for imaging tumor cell death using MRI (11, 12) and, in 99m Tc-labeled form, for imaging tumor cell death (13) and cardiac ischemia using SPECT (14) , and, in 18 F-labeled form, for imaging cell death in a rabbit lung cancer model using PET (15) .
More recently, we have used the isolated C2A domain, (16) , which is much smaller (16 kDa), giving better tissue access and clearance, in which we have introduced a sitedirected mutation (S78C; C2Am) that allows site-specific modification with an imaging label. Studies in vitro demonstrated that this probe showed a four-fold lower binding to viable cells and consequently improved specificity for detecting apoptosis and necrosis, when compared with AnxV (16) . Moreover, removal of the GST tag, which is likely to be immunogenic, should facilitate translation of this agent to the clinic.
We have evaluated here the speed of detection, specificity, sensitivity and biodistribution profiles of AlexaFluor™750-and   99m   Tc-and   111 In-labeled C2Am, for NIRF and SPECT imaging, respectively, of cell death in implanted models of lymphoma (EL4) (11) and colorectal cancer (Colo-205) (17), and in a spontaneous Myc-driven model of Burkitt's lymphoma (Eμ-myc) (18). We also describe a site-directed mutant of C2Am (iC2Am, D108N) that is inactive in phosphatidylserine binding, which we used to demonstrate that there were only low levels of non-specific probe retention.
MATERIALS AND METHODS

Probe expression and chemical labeling
C2Am and iC2Am were expressed, purified and labeled using AlexaFluor™-750 C5-maleimide, maleimide-HYNIC (for 99m Tc) and maleimide-DOTA (for 111 In) as described previously (16) . Successful conjugation was confirmed using electrospray ionization mass spectrometry (ESI-MS) and radio HPLC (Supplemental Figs. 1-2 ).
Phosphatidylserine binding activity of the conjugates was confirmed by surface plasmon resonance measurements (Supplemental Table 1 ). 
Cell culture
Biodistribution and NIRF imaging studies
C2Am-AF750, iC2Am-AF750 or AnxV-750 (Annexin-Vivo™, Perkin Elmer) were administered at 0.10 μmol/kg (10 mL/kg, i.v.) to tumor-bearing NU mice. Imaging in vivo and/or ex vivo was performed using Li-Cor Pearl-Impulse™ or Xenogen IVIS200™ (Perkin Elmer) small animal imaging systems. Li-Cor Imaging Studio software (version 3.1.4) or Perkin Elmer Living Image (version 3.2) were used for image analysis.
Biodistribution and SPECT studies
Twenty-four hours after chemotherapy treatment, tumor-bearing mice received an injection (10 mL/kg, i.v.) of either 
RESULTS
Preparation and characterization of imaging probes
iC2Am-AF750 was produced by site-directed mutagenesis (D108N) of C2Am. This mutation abolishes binding to phosphatidylserine (20). C2Am and iC2Am were prepared and labeled with Alexa Fluor™-750 (C2Am-AF750, iC2Am-AF750), as described previously (16) . The proteins were fully modified, yielding a single molecular species on ESI-MS (Supplemental Fig. 1A-B) . C2Am-AF750, C2Am-HYNIC and C2Am-DOTA bound phosphatidylserine with similar affinities (Kd~60-90 nM; Supplemental Table 1 ), as determined using surface plasmon resonance measurements (16) . As expected, iC2Am-AF750 showed no binding. C2Am was also modified stoichiometrically with maleimide-HYNIC or maleimide-DOTA, generating single species of MW 16426.5 Da, and 16749.8 Da, respectively, as determined by ESI-MS (Supplemental Fig. 1C-D ).
C2Am-HYNIC was loaded with 99m Tc using methods described previously (21). C2Am-DOTA was loaded with 111 InCl3 as described in Supplemental Methods. The conjugates were analyzed by HPLC (Supplemental Fig. 2 ). Radiolabeling efficiency was >94%.
Fluorescence imaging of tumor cell death in vivo
There was increased retention of C2Am-AF750 in drug-treated as compared to untreated EL4 (Fig. 1A, 2A ), Colo-205 (Fig. 1B, 2B ) and Eμ-myc tumors (Fig. 1C, 2C ) at 24 h after probe injection. Anx-AF750 showed no increase in retention following drug treatment in any of the tumor models. Although Anx-AF750 fluorescence was greater than that of C2Am-AF750 in the EL4 tumor model this was not increased by drug treatment. The retention of iC2Am-AF750 in drug-treated tumors was less than of C2Am-AF750 in all of the tumor models and there was no significant difference in the retention of iC2Am-AF750 in untreated or treated Colo-205 (Fig. 2B) and Eμ-myc tumors (Fig. 2C) . In drug-treated EL4 tumors there was an increase in tumor fluorescence in animals injected with iC2Am-AF750 ( Fig. 2A) , however the levels were 3× lower than with C2Am-AF750. This may be due to a treatment-induced increase in the enhanced permeability and retention (EPR) effect in this tumor model (22). The heterogeneous skin pigmentation of Eμ-myc mice prevented accurate optical imaging in vivo and therefore for this tumor model fluorescence was measured ex vivo (Fig. 2C) , which may explain the better contrast observed. All three tumor models showed a correlation between whole tumor mean C2Am-AF750 fluorescence intensities and CC3 staining of histological sections obtained post mortem ( Fig 
Cell binding experiments with 99m
Tc-C2Am
As we were unable to detect treatment response with AnxV-AF750, despite using the In-C2Am showed favorable biodistribution profiles with predominantly renal clearance ( Table 1) . The biodistribution profiles of C2Am-AF750 and iC2Am-AF750 (Supplemental Table   2 ) were similar to those of In-C2Am ( In-C2Am, C2Am-AF750 generated EL4 tumor-to-muscle contrast from as early as 2 h (2.2±0.49) and up to 24 h (3.63±0.4) post injection of the imaging agent (Supplemental Table 2 ).
SPECT imaging of tumor cell death in vivo using 99m
Tc-C2Am and 111
In-C2Am
Images were acquired from animals with implanted Colo-205 ( (P<0.05), paralleling the modest increase and reflecting the wide variation in the levels of cell death in this tumor model (~1.6×; P<0.05). Treatment response was also observed in the spleen and salivary glands of these etoposide-treated animals (Supplemental Fig. 4 and Supplemental video 1).
DISCUSSION
Phosphatidylserine exposed by dying cells constitutes a temporally stable and abundant biomarker for detection of cell death (23). We have been developing the C2Am domain of Synaptotagmin-I, which binds phosphatidylserine with nanomolar affinity, as a cell death imaging agent (16 Tc-C2Am retention (1.9×) (Fig. 6) . In EL4 tumors, despite high levels of pre-existing cell death and a modest increase post treatment (1.6×) (Supplemental Fig. 4B ), Duramycin is a 19-amino acid peptide that binds with high affinity and specificity to the phosphatidylethanolamine externalized by dying cells (30). Tc-labeled duramycin has been used recently to detect response to chemotherapy in a mouse model of colorectal cancer, where accumulation of the agent was found to correlate with markers of cell death (31) . However, the clinical utility of duramycin has yet to be demonstrated.
Imaging agents that target cleaved and activated caspase-3 (CC3), an executioner caspase in the apoptosis pathway, have also been developed for detection of cell death in vivo (25) and a probe capable of detecting CC3 has progressed to clinical trials (32) 
since CC3 is a transient biomarker of cell death, the choice of temporal imaging window following treatment is critical (33) . Furthermore CC3-targeted imaging agents are unable to identify caspase-independent modes of cell death, such as necrosis (34) , which is often present following chemo or radiotherapy.
18
F-ML-10, which appears to bind to dead cells by an unknown mechanism, has shown favorable safety and biodistribution profiles in humans (35) . In a clinical study in ten patients with brain metastasis, there was enhanced retention (up to 2-fold) of 18 F-ML-10 post radiotherapy and a good correlation between probe uptake and tumor size reduction (36) . However, there was no histological demonstration of increased cell death and the average reported decrease in tumor size post therapy was substantial (ca. 60% reduction). Therefore, the utility of Figure 1 . Analysis of imaging probes using electrospray ionization mass spectrometry (ESI-MS).
Supplemental Figure 2. Analysis of 99m
Tc and 111 In labeling of C2Am using gel filtration radio-HPLC. Active (C2Am) and inactive (iC2Am) forms of C2Am-AF750 were prepared using AlexaFluor®750 C5-maleimide (AF750, Invitrogen™, λexc=750 nm, λem=775 nm), following the method described in (1) . Briefly, the protein was reduced in HBS buffer containing 10 mM DTT, for ½ h at room temperature. The protein was then washed in a 5-kDa Vivaspin concentrator in HNE buffer (20 mM, HEPES, 100 mM NaCl, 5 mM EDTA, pH 7.4). The protein was used at a concentration in the range 50-100 μM, and an approximately 10-fold molar excess of the fluorescent maleimide dye was added to the reaction mixture. The reaction was allowed to proceed at 4 °C for 16 h. The modified protein was separated from unreacted dye by gel filtration using a Hi-Load Superdex 75 26/60 preparation grade column (GE Healthcare, Amersham, UK).
Supplemental
Probe radiolabeling with 99m Tc
C2Am-HYNIC was labeled with 99m -Tc pertechnetate ( 99m Tc-C2Am), eluted from an UltraTechnekow™ DTE (Covidien) and supplied at 1.5-2.0 GBq/mL by the Department of Nuclear Medicine (Cambridge University Hospitals), as described previously (2) . To 50 µL of C2Am-HYNIC (715 nmol in 115 mM tricine buffer, pH 6±1), 200 µL of 0.9% degassed saline were added, followed by 20 µL of pertechnetate (ca. 40 MBq) and 20 µL of degassed stannous tricine solution (0.17 mg/mL SnCl2, 6.7 mg/mL tricine and 0.9% NaCl) and the reaction allowed to proceed at room temperature for 10 min. In was removed using a 5-kDa cut-off spin Amicon-ultra filter (Millipore).
All C2Am conjugates were washed and concentrated using Vivapsin concentrators and analyzed by Electrospray Ionization Mass Spectrometry (ESI-MS) (1) (Supplemental Figure 1) .
Cell binding assays using 99m
Tc-C2Am
Etoposide-treated (15 µM, 24 h) or untreated EL4 cells were washed in ice-cold HBS + buffer (HBS with 2 mM CaCl2), pelleted (600g, 4°C, 4min), and re-suspended in the same buffer at 1x10 
SPECT studies
A NanoSPECT system (Bioscan Inc.) with 4 detector heads (230×215 mm; sodium iodide crystals) with multiple pinholes (36×2.0mm) was used. A minimum of 50,000 counts/projection were collected and the data reconstructed to give an isotropic resolution of 300 μm. CT images were acquired by helical acquisition using a microtomography system (NanoPET/CT, Mediso) and reconstructed using a modified cone beam filtered back projection method using a Butterworth filter to give an isotropic resolution of 212 μm. SPECT and CT images were fused and radioactivity quantified using VivoQuant TM 1.22 (InviCRO), and rendered in 3D for detailed visualization.
Immunohistochemistry and ex vivo imaging of tissue fluorescence
Excised tissues were weighed, radioactivity measured as described above and approximately half of each specimen was placed in 10% neutral buffered formalin (NBF, 10%, Acquascience). Unstained tissue sections were de-waxed and rehydrated and slides mounted using Prolong Gold™ antifade reagent (Life Technologies), cured for 24 h at room temperature, prior to microscopic NIRF imaging at a resolution of 21 μm, using a Odyssey™ (Li-Cor) flat-bed scanner. Tissues fixed for 24 h in NBF were transferred into 70% ethanol and sections (3-μm) cut using a rotary microtome. Hematoxylin and eosin (H&E) staining was performed on a Leica ST5020/CV5030 workstation (Leica Biosystems). Fixed effects for dose, protein and the dose*protein interaction were considered. Random effects were fitted for dose nested within tumor nested within mouse. During the model building process, random effects were compared using restricted maximum likelihood (REML) and fixed effects were compared using maximum likelihood (ML). The final model was fitted using REML. The analysis was conducted in R software vs. 2.14.1, using the nlme package (version 3.1.102). The R output for the final model is given below.
In a mixed effect model, usually only the parameter estimates for the fixed effects are interpreted. The results of the fixed effects part of the model are given in Table A . The results in Table A can be interpreted as follows:
• The difference between the pre-and post-treatment stages is 0.318 (0.034+0.284) SUV units for C2Am. Residual plots were used to check for normality of the model residuals and these were satisfactory.
Post-hoc tests were performed to compare pre-and post-treatment measurements for each protein separately. This part of the analysis was conducted in R 2.14.1, using the multcomp package (version 1.2.17). The results are given in Table B . The P-values were adjusted for multiple testing using a Bonferroni correction. The difference between the pre-and post-treatment measurements was significant for C2Am.
R output for final model:
> #Final model > > m.final <-lme(Response ~ Protein + relevel(Dose,ref="Pre") + Protein*relevel(Dose,ref="Pre"), random=~1|ID/Tumour/Dose, data=mydata, method="REML", na. 
Supplemental Figure 1.
Analysis of imaging probes using electron spray ionization mass spectrometry (ESI-MS). In-labeling of C2Am using gel filtration radio-HPLC. Tc-labeled C2Am was 94%.
(B)
111
In-C2Am-DOTA, the main species at 9.183 min in the radioactivity channel, was (ii) Analysis of CC3 staining.
(iii) Spleen cellularity decreases with treatment.
Spleen sections (ii,iii) from untreated (n=20) or treated (n=10) mice were analyzed in each group. *P<0.05, **P<0.005, ***P<0.001, differences between groups (i, ii) were significant t-test.
Supplemental Figure 4.
SPECT imaging of cell death in vivo in EL4 tumors.
Imaging of 
